Source comparison
MK-677 vs HGH Comparison Cost Results: Full Breakdown
Mechanism Ghrelin receptor agonist stimulating endogenous pulsatile GH release Exogenous bioidentical growth hormone administered subcutaneously MK-677 works within physiological limits; HGH bypasses them entirely Monthly Cost $80–150 for research-grade 25mg d
This comparison does not assign a generated winner or score.
- Mechanism
- Ghrelin receptor agonist stimulating endogenous pulsatile GH release
- Exogenous bioidentical growth hormone administered subcutaneously
- MK-677 works within physiological limits; HGH bypasses them entirely
- Monthly Cost
- $80–150 for research-grade 25mg daily dosing
- $500–2,000+ depending on dose (2–6 IU daily) and source
- 10–20× cost differential reflects regulatory classification, not just manufacturing
- IGF-1 Increase
- 60–90% above baseline (from ~150 ng/mL to 240–285 ng/mL)
- 150–300% above baseline (from ~150 ng/mL to 375–600 ng/mL) dose-dependent
- HGH produces 2–3× greater IGF-1 elevation at therapeutic doses
- Lean Mass Gain (12 weeks)
- 1–2 kg typical in resistance-trained subjects
- 2–4 kg typical at 4–6 IU daily with structured training
- HGH's anabolic effect is dose-dependent and more pronounced
- Fat Loss (12 weeks)
- 1–2% body fat reduction (primarily visceral)
- 2–4% body fat reduction (subcutaneous and visceral)
- HGH mobilizes adipose tissue more aggressively through direct lipolytic signaling
- Pituitary Suppression
- None. Preserves endogenous GH production
- Significant. Endogenous production suppressed 4–8 weeks post-cessation
- MK-677 discontinuation requires no PCT; HGH requires axis recovery period
- Primary Side Effects
- Increased appetite (60–80%), transient water retention, mild glucose elevation
- Joint pain (30–50%), carpal tunnel (10–20%), insulin resistance, fluid retention
- MK-677 effects manageable; HGH effects often require dose reduction or ancillaries